A Randomized Controlled, Open-lable, Phase III, Multicenter Clinical Study of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation
To assess the efficacy and safety of Almonertinib versus platinum-based chemotherapy as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutation.
Indication: Non-small Cell Lung Cancer
Modality: small molecule
Target: Almonertinib, chemotherapy
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Source URL: ClinicalTrials.gov
Source updated: Jul 07, 2021
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Almonertinib, chemotherapy
View original source fields
Condition raw: Non-small Cell Lung Cancer
Condition normalized: Non-small Cell Lung Cancer
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Almonertinib, chemotherapy
Target normalized: Almonertinib, chemotherapy